Endovascular Stent Grafting for Recurrent Strokes Due to Fragile Innominate Artery Plaque: A Case Report

Takaaki ISHIKAWA,1 Tomosato YAMAZAKI,1 Masataka SATO,2 Noriyuki KATO,1 Eiichi ISHIKAWA,3 Yuji MATSUMARU,3 and Akira MATSUMURA3

1Department of Neurosurgery, National Hospital Organization, Mito Medical Center, Ibaraki, Ibaraki, Japan
2Department of Cardiovascular Surgery, National Hospital Organization, Mito Medical Center, Ibaraki, Ibaraki, Japan
3Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

Abstract

Here we describe a case of recurrent ischemic strokes due to fragile innominate artery plaque successfully treated using endovascular stent grafting. An 80-year-old man presented with a history of recurrent strokes that were refractory to medical treatment. Computed tomography and magnetic resonance images of the thorax revealed a gross intramural plaque in the innominate artery. He was successfully treated using endovascular stent grafting. An AFX stent graft device was used to prevent further embolic strokes. The AFX stent graft has a unique endoskeleton design with a thin-walled expanded polytetrafluoroethylene fabric—known as active sealing structure—attached to the implant. Postoperatively, the patient has experienced no recurrent strokes in over 2 years of follow-up. The stent grafting procedure could be an optimal treatment option for treating fragile innominate artery plaques.

Keywords: innominate artery, fragile plaque, recurrent stroke, endovascular stent grafting, magnetization-prepared rapid acquisition gradient echo

Introduction

Stenotic lesions of the supraaortic vessels are a major cause of ischemic stroke resulting from either hemodynamic compromise or an artery-to-artery embolism. Regarding extracranial carotid artery stenosis, there have been some data on interventions such as carotid endarterectomy or carotid artery stenting for the prevention of further ischemic strokes.1 However, as data of stenotic lesion in the innominate artery (IA) are scarce, the natural course is not well known and the optimal treatment indications as well as the strategy are not established.2 Particularly, embolic strokes originating from IA plaque are very rarely seen as stroke etiology. Herein, we report a case with repeated stroke originating from an intraluminal plaque in the IA, successfully treated with endovascular stent grafting. The patient’s wife provided written consent for this report.

Case Report

An 80-year-old man with a long history of hypercholesterolemia and diabetes mellitus presented at our hospital with an abrupt onset of left mild hemiparesis. Over the past 10 years, he had been admitted six times because of recurrent ischemic strokes despite taking antiplatelet medications, direct oral anticoagulants, and statin medications. The etiology of recurrent strokes had not been clearly identified so far and the IA was not examined before. On arrival at the hospital, he had the same blood pressure on both arms. There were no remarkable laboratory findings including coagulation activity and platelet counts. The lipid profile revealed a total cholesterol of 191 mg/dL; a low-density lipoprotein cholesterol (LDL-C) of 130 mg/dL; a high-density lipoprotein cholesterol (HDL-C) of
38 mg/dL; and LDL/HDL ratio of 3.4 and triglycerides of 102 mg/dL. Magnetic resonance imaging (MRI) of the brain showed new ischemic lesions on the diffusion-weighted images as well as old ischemic lesions on the fluid-attenuated inversion recovery images in the right hemisphere (Figs. 1A and 1B). Magnetic resonance angiography of the head and neck revealed no significant stenosis responsible for recurrent ischemic strokes. No abnormalities were detected on electrocardiography, Holter.
electrography, or echocardiography. Computed tomography (CT) of the thorax with contrast enhancement revealed a gross intramural hematoma in the IA (Fig. 2A). MRI using the magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence revealed a high-intensity lesion on T1 in the corresponding intramural plaque (Figs. 2B and 2C), indicating a lipid-rich, large and fragile plaque, which was thought to be the cause of the repeated embolic strokes. We decided to use endovascular stent grafting to seal the plaque with distal protection to avoid embolic complications during the procedure, hereby prevent further ischemic strokes. The AFX Endovascular AAA Stent Graft System (Endologix, Inc., Irvine, CA, USA) was employed in terms of plaque sealing and size of the IA and informed consent regarding off label use of this stent graft device for the IA was obtained from the patient and his wife.

Procedure
Surgery was performed under general anesthesia. First, the right brachial artery as well as the right common carotid artery (CCA) was exposed to avoid postoperative puncture site complications such as hematoma and pseudoaneurysm formation. A 7-French 25-cm double lumen sheath (Medikit, Tokyo, Japan) was inserted into the right brachial artery while a 5-French 10-cm sheath (Medikit) was inserted into the right CCA. For embolic protection, the Percu-Surge GuardWire (Medtronic, Minneapolis, MN, USA) was introduced from one lumen of the 7-French double lumen sheath into the right vertebral artery (VA) and inflated. Meanwhile, the CCA was temporarily clamped with vascular tape just distal to the 5-French sheath whenever a device passed through the IA lesion. Once these distal protections were prepared, a 260 cm Amplatz Super Stiff Guidewire (Boston Scientific, Boston, MA, USA) was introduced from the CCA sheath into the ascending aorta to deploy the stent graft. A pigtail catheter (Merit Medical, South Jordan, UT, USA) was navigated through the other lumen of the 7-French double lumen sheath into the ascending aorta for the aortography. The degree of stenosis and the length of the lesion were measured with the aortography (Fig. 3A), and the decision was made to use the AFX Endovascular AAA System limb extension stent graft with a diameter of 20 mm and length of 55 mm. The pigtail catheter inserted from 7-French double lumen sheath was pulled back to the subclavian artery. A stent graft delivery sheath was advanced over the Amplatz Super Stiff Guidewire. From the delivery sheath, the stent graft was deployed in the IA under fluoroscopic guidance (Fig. 3B). Aortography was used to confirm that the IA lesion was covered with the stent graft (Fig. 3C). The distal protections of the CCA and VA were reopened while blood was aspirated until no debris was observed. The wounds were closed and the general anesthesia was discontinued.

Postoperative course
No neurological complication was observed clinically or radiologically. The patient (with modified Rankin Scale of 3) was transferred to a nursing home, and
followed up at our outpatient clinic with neurological examination every 3 months and MRI every 6 months. After 2 years of follow-up, no recurrent strokes have been observed clinically or on MRI. Postoperative CT angiography at 8 months showed no evidence of restenosis or in-stent thrombosis (Fig. 4).

**Discussion**

Although embolism from the atheromatous plaque in the IA is recognized as a possible cause of recurrent stroke, only a few cases have been reported. IA stenosis comprises 0.5–2% of all extracranial causes of cerebrovascular insufficiency. However, there have been no reports regarding the reasons that explain a low incidence of IA atheromatous lesions causing stroke to date. It may be related to anatomical differences that the IA supplies blood to not only the brain but also the right upper extremity, compared to the carotid artery or other intracranial arteries. However, more importantly, it is assumed that the IA is not routinely examined for the stroke work-up in a daily clinical practice and the risk of embolic stroke originating from IA atheromatous plaque could be often overlooked or under-detected. Thus, it is important to keep in mind that a thorough systematic search for the embolic sources may be necessary and that the aorta and its main branches should be recognized as possible cause of the embolic stroke.

In carotid atherosclerotic lesions, vascular imaging such as the evaluation for plaque vulnerability with MRI has been well studied. A variety of T1-weighted sequences including MPRAGE, time of flight, and conventional sequences can be used to assess plaque instability. Of these, high intensity on MRI T1-weighted images using the MPRAGE sequence is useful for identifying lipid-rich and fragile plaques, which carry a high risk of artery-to-artery embolism. We applied these plaque imaging techniques to the thoracic aorta and its main branches. MRI using the MPRAGE sequences and CT with contrast enhancement in the thorax clearly demonstrated an intramural large fragile plaque in the IA, which we determined to be the lesion responsible for the recurrent ischemic strokes.

Managing risk factor controls including hypertension, dyslipidemia, diabetes, cigarette smoking, and so on play an important role in preventing stroke recurrence of atherosclerotic origin, in addition to antithrombotic medications. He has a long history of hyperlipidemia and his LDL-C level on admission was 130mg/dL despite of taking statin medications. The Treat Stroke to Target trial revealed that after an ischemic stroke or TIA with evidence of atherosclerosis, patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those who had a target range of 90 mg to 110 mg per deciliter. Moreover, the subanalysis of the JELIS trial revealed administration of highly purified eicosapentaenoic acid (EPA) appeared to reduce the risk of recurrent stroke in a Japanese population of hypercholesterolemic patients receiving low-dose statin therapy. Therefore, if IA atheromatous plaque lesion had been detected earlier, stricter control of LDL-C as well as highly purified EPA administration should have been considered.

There have been some case series addressing stent placement for the IA stenotic lesions. However, symptoms in the majority of previous case series were hemodynamic compromise such as upper limb claudication or upper limb arterial pressure asymmetry while some are even without any clinical symptoms. The treatment indications were varied. More importantly, plaque characteristics (calcified, fragile, or fibrous), identified through vascular imaging, were not evaluated. Various types of stents (balloon expandable bare stents, self-expandable bare stents, and balloon expandable covered stents) were used, although the rationale behind selecting those various
types of stents were not detailed. In the present case, with recurrent strokes due to a gross fragile plaque, we selected the AFX stent graft device as being the most suitable from the standpoint of its plaque-sealing capacity and the vessel diameter of the IA (larger and shorter than other supraaortic branch arteries).\textsuperscript{7,15} The self-expandable AFX stent graft device is known for its endoskeleton design and active sealing structure in which the propriety expanded polytetrafluoroethylene (ePTFE) graft material is externally mounted. This stent provides weak radial force and, thereby, avoids putting excessive stress on a fragile plaque.\textsuperscript{16} This stent also provides conformability for the irregularities of the vessel wall. In addition, open surgical CCA clamping as well as balloon protection for right VA achieved no ischemic complication. Two years after the stent grafting, the patient has not experienced any recurrence of stroke. The success of the treatment in the case presented here provides valuable insights for establishing the optimal treatment indication, strategy, and preferred type of stents for IA atheromatous plaque lesion.

Acknowledgments

The authors thank Dr. Alexander Zaboronok, Department of Neurosurgery, and Thomas Mayer of the Medical English Communications Center of the Faculty of Medicine, University of Tsukuba, for manuscript revision.

Conflicts of Interest Disclosure

The authors declare that there is no conflict of interest.

References

1) Sardar P, Chatterjee S, Aronow HD, et al.: Carotid artery stenting versus endarterectomy for stroke prevention: a meta-analysis of clinical trials. \textit{J Am Coll Cardiol} 69: 2266–2275, 2017
2) de Borst GJ: Innominate artery stenting: the continuing saga of “who, when, and how”? \textit{J Endovasc Ther} 26: 391–393, 2019
3) Moustafa R, Antoun NM, Coulden RA, Warburton EA, Baron JC. Stroke attributable to a calcific embolus from the brachiocephalic trunk. \textit{Stroke} 37: 668, 2006
4) Nakajima M, Yasaka M, Minematsu K: Mobile thrombus from a ruptured plaque in the brachiocephalic artery. \textit{J Stroke Cerebrovasc Dis} 17: 423–425, 2008
5) Oishi Y, Hirahara N, Takaseya T, Kawara T, Yasaka M, Morita S: Gift replacement for massive embolic source in brachiocephalic artery. \textit{Asian Cardiovasc Thorac Ann} 16: e58–e59, 2008
6) Watari M, Nakajima M, Nishitomi-Izumida M, Inatomi Y, Yonehara T, Hirano T: Dynamic migration of a mobile plaque from the brachiocephalic artery detected by ultrasonogram. \textit{Echocardiography} 30: e28–e29, 2013
7) Paukovits TM, Lukács L, Bérczi V, Hirschberg K, Nemes B, Hüttl K: Percutaneous endovascular treatment of innominate artery lesions: a single-centre experience on 77 lesions. \textit{Eur J Vasc Endovasc Surg} 40: 35–43, 2010
8) Hatsuksami TS, Yuan C: MRI in the early identification and classification of high-risk atherosclerotic carotid plaques. \textit{Imaging Med} 2: 63–75, 2010
9) Gupta A, Baradaran H, Schweizter AD, et al.: Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. \textit{Stroke} 44: 3071–3077, 2013
10) Kernan WN, Ovbiagele B, Black HR, et al.: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/Ameri can Stroke Association. \textit{Stroke} 45: 2160–2236, 2014
11) Hackam DG, Hegele RA: Cholesterol lowering and prevention of stroke. \textit{Stroke} 50: 537–541, 2019
12) Amaral P, Kim JS, Labreuche J, et al.: A comparison of two LDL cholesterol targets after ischemic stroke. \textit{N Engl J Med} 382: 9, 2020
13) Tanaka K, Ishikawa Y, Yokoyama M, et al.: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. \textit{Stroke} 39: 2052–2058, 2008
14) Ammi M, Henni S, Salomon Du Mont L, et al.: Lower rate of restenosis and reinterventions with covered vs bare metal stents following innominate artery stenting. \textit{J Endovasc Ther} 26: 385–390, 2019
15) Mordasini P, Gralla J, Do DD, et al.: Percutaneous and open retrograde endovascular stenting of symptomatic high-grade innominate artery stenosis: technique and follow-up. \textit{AJNR Am J Neuroradiol} 32: 1726–1731, 2011
16) Diethrich EB: Novel sealing concept in the Endologix AFX unibody stent-graft. \textit{J Cardiovasc Surg (Torino)} 55: 93–102, 2014

Corresponding author: Tomosato Yamazaki, MD, PhD
Department of Neurosurgery, National Hospital Organization, Mito Medical Center, 280 Sakuranosato, Ibaraki, Ibaraki 311-3193, Japan.

\textit{NMC Case Report Journal} 8, February, 2021
